Assurex Health and CAMH Awarded $6 Million Grant from Genome Canada To Study Benefits of Genetic Testing to Guide Mental Health Medication Decisions

Assurex Health and Canada’s Centre for Addiction and Mental Health (CAMH) today announced they have received a $6 million grant from Genome Canada, an agency of the Canadian government, to study the benefits of genetic testing to guide medication decisions for patients with depression or schizophrenia. Read more.

Medicare for the First Time to Cover Combinatorial Genetic Testing to Guide Individualized Selection of Depression Medications

Medicare has issued a Local Coverage Determination (LCD) that will provide coverage for GeneSight Psychotropic, the first combinatorial pharmacogenomic test to help guide medication decisions for depression. Prior to GeneSight, no psychiatric pharmacogenomic test has achieved a favorable coverage decision from Medicare. There is no out-of-pocket cost to Medicare Part B patients. Read more.

Assurex Health Announces International Expansion through Canadian Partnership with the Centre for Addiction and Mental Health

In November 2013, CAMH and Assurex Health signed a partnership agreement to bring the benefits of a personalized approach to psychiatric treatment to more Canadians. One year later, Canadian patients enrolled in the IMPACT study are being tested using Assurex Health proprietary technology, GeneSight® Psychotropic. Read more.

For the best and most secure experience using myGeneSight, we recommend upgrading your browser to a newer version or switching to a supported browser.

You can continue using your browser for the time being, but myGeneSight may not function as expected.

We support the latest versions of Chrome, Safari, Firefox, Internet Explorer, and Edge.

Please enter your email address below. If you are not sure which email to specify, please call Customer Service at 1.866.757.9204 or email